Toggle Nav
Close
  • Menu
  • Setting

Sorafenib

Catalog No.
A3009
Raf kinases and tyrosine kinases inhibitor
Grouped product items
SizePriceStock Qty
10mM (in 1mL DMSO)
$61.00
In stock
Evaluation Sample
$30.00
In stock
500mg
$72.00
In stock
1g
$110.00
In stock
For scientific research use only and should not be used for diagnostic or medical purposes.

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

Background

Sorafenib (CAS 284461-73-0) is an orally bioavailable small molecule inhibitor targeting multiple kinases, including Raf kinase as well as receptor tyrosine kinases such as VEGFR2, PDGFR, FLT3, Ret, and c-Kit. By inhibiting Raf signaling pathways, sorafenib suppresses tumor cell proliferation, induces apoptosis, and disrupts tumor angiogenesis. In vitro studies demonstrate that sorafenib effectively inhibits Raf-mediated signaling cascades and blocks the proliferation of tumor cells. Sorafenib serves as an important research tool in the study of cancer biology, particularly in investigating antiangiogenic and antiproliferative mechanisms in various tumor models.

Product Citation

Chemical Properties

Physical AppearanceA solid
StorageStore at -20°C
M.Wt464.82
Cas No.284461-73-0
FormulaC21H16ClF3N4O3
SynonymsBAY-43-9006, Sorafenib, Nexavar, sorafenibum
Solubility≥23.25 mg/mL in DMSO; insoluble in H2O; insoluble in EtOH
Chemical Name4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide
SDFDownload SDF
Canonical SMILESCNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F
Shipping ConditionSmall Molecules with Blue Ice, Modified Nucleotides with Dry Ice.
General tips We do not recommend long-term storage for the solution, please use it up soon.

Protocol

Cell experiment: [1]

Cell lines

PLC/PRF/5 and HepG2 cells

Preparation method

The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37°C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Reaction Conditions

IC50: 6.3 μM for PLC/PRF/5 cells 4.5 μM for HepG2 cells 72 hours

Applications

The effect of sorafenib on cell proliferation was measured by CellTiter-Glo assay. Sorafenib inhibited cell proliferation dose-dependently with an IC50 of 6.3 μmol/L in PLC/PRF/5 and 4.5 μmol/L in HepG2 cells.

Animal experiment: [1]

Animal models

Female CB17 SCID mice injected with PLC/PRF/5 cells

Dosage form

Oral administration; 10, 30, and 100 mg/kg body weight; once daily for 16 or 21 days

Applications

Sorafenib tosylate produced dose-dependent growth inhibition of s.c. implanted PLC/PRF/5 tumor xenografts in SCID mice. Dose levels of 10 and 30 mg/kg produced significant and dose-dependent TGIs of 49% and 78%, respectively. Sorafenib tosylate produced durable partial tumor regressions in 50% of the mice at the 100 mg/kg dose level.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

[1] Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer research, 2006, 66 (24): 11851-11858.

Biological Activity

Description Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM, respectively.
Targets   B-Raf VEGFR2 PDGFRβ    
IC50 6 nM 22 nM 90 nM 57 nM    

Quality Control

Chemical structure

Sorafenib

Related Biological Data

Sorafenib

Related Biological Data

Sorafenib

Related Biological Data

Sorafenib

Related Biological Data

Sorafenib

Related Biological Data

Sorafenib

Related Biological Data

Sorafenib

Related Biological Data

Sorafenib